16,928 Shares in Regeneron Pharmaceuticals, Inc. $REGN Acquired by Great Lakes Advisors LLC

Great Lakes Advisors LLC acquired a new stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 16,928 shares of the biopharmaceutical company’s stock, valued at approximately $10,555,000.

A number of other institutional investors have also recently added to or reduced their stakes in the business. WPG Advisers LLC increased its stake in shares of Regeneron Pharmaceuticals by 312.5% during the 4th quarter. WPG Advisers LLC now owns 33 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 25 shares during the last quarter. SHP Wealth Management bought a new position in shares of Regeneron Pharmaceuticals during the 4th quarter valued at $26,000. Western Wealth Management LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the 1st quarter valued at $26,000. Titan Wealth CI Ltd acquired a new stake in shares of Regeneron Pharmaceuticals in the 4th quarter valued at $29,000. Finally, Mowery & Schoenfeld Wealth Management LLC bought a new stake in Regeneron Pharmaceuticals in the second quarter worth $29,000. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other news, Director Arthur F. Ryan sold 200 shares of the firm’s stock in a transaction dated Thursday, July 2nd. The shares were sold at an average price of $650.15, for a total transaction of $130,030.00. Following the completion of the transaction, the director directly owned 17,303 shares of the company’s stock, valued at approximately $11,249,545.45. This trade represents a 1.14% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kathryn Guarini sold 400 shares of Regeneron Pharmaceuticals stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $800.00, for a total transaction of $320,000.00. Following the sale, the director owned 603 shares in the company, valued at approximately $482,400. This trade represents a 39.88% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 1,400 shares of company stock valued at $1,090,030 in the last 90 days. 6.97% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several research firms have commented on REGN. HSBC lowered their target price on shares of Regeneron Pharmaceuticals from $990.00 to $880.00 and set a “buy” rating on the stock in a research report on Monday, July 6th. Wells Fargo & Company boosted their price target on Regeneron Pharmaceuticals from $700.00 to $750.00 and gave the stock an “equal weight” rating in a research report on Friday, July 31st. Canaccord Genuity Group decreased their price target on Regeneron Pharmaceuticals from $1,057.00 to $875.00 and set a “buy” rating for the company in a research note on Tuesday, May 19th. Sanford C. Bernstein raised Regeneron Pharmaceuticals to a “hold” rating in a report on Wednesday, July 29th. Finally, Wall Street Zen raised Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday. Sixteen investment analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company. According to MarketBeat, Regeneron Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $801.70.

Trending Headlines about Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Leerink raises price target: Leerink Partners increased its REGN price target from $641 to $824, implying modest additional upside. However, the firm retained a “market perform” rating, suggesting limited conviction in a stronger near-term advance. Benzinga analyst price target report
• Neutral Sentiment: Class-action deadline approaches: Several law firms, including Pomerantz, Hagens Berman, Faruqi & Faruqi, and The Schall Law Firm, reminded investors of a September 14, 2026 deadline to seek lead-plaintiff status in a securities lawsuit. These announcements largely repeat previously reported information and do not represent a new financial or regulatory finding. Pomerantz investor alert
• Negative Sentiment: Litigation highlights clinical-trial concerns: The lawsuits allege that Regeneron made misleading statements about clinical differentiation and slowing event accrual in the Phase 3 fianlimab-Libtayo study, potentially understating the risk that the trial would miss its primary endpoint. The trial failure reportedly erased roughly $11 billion in market value and could create ongoing legal costs, reputational risk, and uncertainty around the program’s commercial prospects. The allegations have not been proven. Hagens Berman Regeneron class-action notice

Regeneron Pharmaceuticals Trading Up 0.5%

Regeneron Pharmaceuticals stock opened at $810.24 on Wednesday. The business has a 50 day moving average price of $683.57 and a two-hundred day moving average price of $714.66. The company has a quick ratio of 2.78, a current ratio of 3.34 and a debt-to-equity ratio of 0.06. The stock has a market cap of $83.42 billion, a price-to-earnings ratio of 20.03, a price-to-earnings-growth ratio of 1.37 and a beta of 0.21. Regeneron Pharmaceuticals, Inc. has a 12 month low of $541.00 and a 12 month high of $821.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $14.29 EPS for the quarter, topping analysts’ consensus estimates of $10.16 by $4.13. The company had revenue of $4.29 billion during the quarter, compared to the consensus estimate of $3.82 billion. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%.The company’s quarterly revenue was up 16.7% on a year-over-year basis. During the same quarter last year, the company earned $12.81 EPS. As a group, equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post 44.25 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, August 31st. Shareholders of record on Tuesday, August 18th will be paid a dividend of $0.94 per share. The ex-dividend date is Tuesday, August 18th. This represents a $3.76 dividend on an annualized basis and a yield of 0.5%. Regeneron Pharmaceuticals’s payout ratio is currently 9.29%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.